|

This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

RECRUITINGPhase 1Sponsored by LTZ Therapeutics, Inc.
Actively Recruiting
PhasePhase 1
SponsorLTZ Therapeutics, Inc.
Started2026-12
Est. completion2031-12
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with unresectable or metastatic colorectal cancer and other solid tumors failing standard therapies.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Advanced /metastatic colorectal tumors that have failed standard treatments
* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
* Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1
* Adequate organ function based on laboratory testing

Exclusion Criteria:

* Active infection with hepatitis B or C
* Uncontrolled CNS metastases
* Active autoimmune disease
* Clinically significant cardiovascular disease not adequately controlled with medication or impaired function
* Previous treatment with EpCAM targeting agent
* Pregnant or breast feeding
* Non-colorectal active malignancy within 3 years that could interfere with study interpretation

Conditions6

Advanced / Metastatic Solid TumorCancerColon CancerColorectal CancerEPCAMSolid Tumor (Phase I)

Interventions1

Locations1 site

HonorHealth Research Institute
Scottsdale, Arizona, 85258
Stephanie Stanford480-323-1350stsanford@honorhealth.com

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.